Scientific deep-dive

Bone Density on a GLP-1: The Trial That Compared It Against Exercise

A four-arm randomized trial found liraglutide alone lost hip and spine bone density relative to exercise, while the combined arm had the greatest weight loss and kept bone density level with placebo.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·2 citations

One randomized trial put the question directly: after losing weight, does it matter how you keep it off, as far as your bones are concerned? Adults with obesity spent eight weeks on a very low calorie diet, then a year on exercise, liraglutide, both, or placebo. Liraglutide alone lost bone mineral density at the hip and spine relative to exercise. The combination held bone density level with placebo while producing the largest weight loss of the four groups.[1]

The four-arm trial

One hundred and ninety-five adults aged 18 to 65 with a BMI between 32 and 43, none of them diabetic, completed an eight-week 800 kcal/day diet and were then randomized for 52 weeks to a moderate-to-vigorous exercise program, liraglutide 3.0 mg daily, both, or placebo. Bone mineral density at hip, lumbar spine and distal forearm was measured by DXA from before the diet to the end of treatment.[1]

Total estimated mean weight loss across the study, by arm (n = 195).[1]
ArmWeight loss95% CI
Placebo7.03 kg4.25–9.80
Exercise alone11.19 kg8.40–13.99
Liraglutide alone13.74 kg11.04–16.44
Combination16.88 kg14.23–19.54

Now the bone results, which do not follow the weight results. Against placebo, the combination group’s bone mineral density was unchanged at the hip (−0.006 g/cm², P = .24) and lumbar spine (−0.010 g/cm², P = .20), even though that group lost more than twice as much weight. Against exercise, liraglutide alone decreased bone density at the hip (−0.013 g/cm², P = .03) and spine (−0.016 g/cm², P = .04).[1]

The combination arm lost more than twice the weight of placebo, and its hip and spine bone density was unchanged against placebo.
This is a predefined secondary analysis of a trial whose primary purpose was elsewhere. Predefined is much better than post-hoc. Still, 195 people across four arms is roughly 49 per arm, which is small for a bone-density endpoint. Treat it as the best available randomized answer rather than a definitive one.

And a meta-analysis that points the other way

A 2025 systematic review pooled 25 randomized trials in people with type 2 diabetes and found the opposite direction. GLP‑1 receptor agonists came out superior to control on lumbar spine BMD (+0.07 g/cm²), hip neck BMD (+0.05) and total hip BMD (+0.06), all highly significant, with no significant increase in fracture risk (RR 0.80, 95% CI 0.47–1.36).[2]

Both results stand, because they measure different things. The trial studied people without diabetes and compared the drug against exercise. The meta-analysis studied people with diabetes and compared against control. Diabetes itself damages bone quality, and improving glucose control plausibly helps it; in someone without diabetes there is no such deficit to repair, and what remains is the bone loss that accompanies losing weight.

Why two good sources disagree.
The randomized trial[1]The meta-analysis[2]
PopulationObesity, no diabetesType 2 diabetes
ComparatorExercise, and placeboControl
FindingLiraglutide alone lost hip and spine BMD vs exerciseGLP-1 RAs superior on spine, hip neck and total hip BMD
FractureNot the endpointNo significant increase (RR 0.80)

What follows from it

  • The trial's practical message concerns the exercise: the arm combining both held bone density while losing the most weight.
  • Exercise is the intervention with randomized support here. In this trial that meant vigorous interval cycling plus circuit training that included strength work.[1] The muscle literature points the same way, toward resistance training.
  • Fractures were not the trial's endpoint, and no fragility fractures were reported in any group.[1] The meta-analysis did test fracture risk and found no significant increase.[2]
  • If you have type 2 diabetes, the pooled evidence in your population points toward benefit rather than harm.
  • Bone density is one input to fracture risk, not the whole of it. Whether you need a DXA scan is a clinical judgment, not one this article can make.

Our companion page on bone density and fracture risk covers the fracture question in its own right, and what the body-composition studies measured sets out the parallel finding for muscle. There, too, resistance training is the only intervention with randomized backing.

Frequently Asked Questions

It depends on the population and what you compare against. In a randomized trial of adults with obesity and no diabetes, liraglutide alone lost bone mineral density at hip and spine relative to exercise. In a meta-analysis of 25 trials in people with type 2 diabetes, GLP-1 receptor agonists were superior to control on spine and hip bone density.
In this trial it appears to. The group taking liraglutide plus exercise lost the most weight of any arm (16.88 kg), and its bone mineral density was statistically unchanged against placebo at both hip and lumbar spine.
The meta-analysis of 25 randomized trials found no significant association with increased fracture risk, at a relative risk of 0.80 with a confidence interval spanning 0.47 to 1.36.
They studied different people against different comparators. The trial enrolled adults without diabetes and compared the drug against exercise; the meta-analysis pooled trials in type 2 diabetes against control. Diabetes itself harms bone quality, so improving glucose control may help bone in that group while offering nothing to someone without the condition.

References

  1. 1.Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial JAMA Network Open. 2024. PMID: 38916894.
  2. 2.Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. 2025. PMID: 39985672.

Plant-Based Protein on a GLP-1: What Closes the Gap, and Why the Drug Widens It

Across a full day at high protein intake a vegan diet matched an omnivorous one for muscle. Per meal, an omnivorous meal produced about 47% more muscle protein synthesis than a vegan one, and a GLP-1 works against the intake that closes the gap.

7 min read

Ozempic Butt: What Large Weight Loss Changes in the Buttocks

No trial has measured buttock shape on semaglutide or tirzepatide. What changes is gluteal fat, some gluteal muscle and skin that does not retract, the same as with any large weight loss. What the DXA and MRI data show, what resistance training keeps, and what surgery can do.

11 min read

Exercise Plus a GLP-1: What Each One Actually Changes

In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.

6 min read

Protein Targets and the Lab Panel

At least 1.2 g of protein per kg daily, 0.3–0.4 g/kg per meal, and a short lab panel: vitamin D, B12, iron studies, folate and zinc, plus thiamin in high-risk patients. The upper protein target excludes chronic kidney disease.

5 min read

MK-677: A Real Trial in Eight People, and a Liver Report

A 1998 randomized crossover trial found MK-677 reversed diet-induced protein catabolism, moving nitrogen balance from -2.67 to +0.31 g/day. It enrolled eight people and measured a proxy. A 2025 case report describes liver injury after two months of use.

5 min read

Muscle Volume Versus Muscle Function on a GLP-1

Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people, and only one of them is what anybody wants.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.3

Ivim Health

Coaching and unlimited provider visits bundled into a 12-month compounded program

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →